ValuEngine upgraded shares of Genomic Health (NASDAQ:GHDX) from a sell rating to a hold rating in a report issued on Friday.

Several other equities research analysts have also weighed in on GHDX. BidaskClub raised Genomic Health from a sell rating to a hold rating in a research note on Saturday, August 26th. Cowen reissued a hold rating and set a $34.00 price objective on shares of Genomic Health in a research note on Friday, September 1st. Jefferies Group reissued a hold rating and set a $33.00 price objective on shares of Genomic Health in a research note on Thursday, September 14th. Canaccord Genuity reissued a buy rating and set a $35.00 price objective on shares of Genomic Health in a research note on Wednesday, September 27th. Finally, Zacks Investment Research lowered Genomic Health from a hold rating to a sell rating in a research note on Wednesday, October 4th. Two analysts have rated the stock with a sell rating, eight have issued a hold rating and one has given a buy rating to the stock. The stock presently has an average rating of Hold and an average target price of $31.57.

Shares of Genomic Health (NASDAQ GHDX) opened at $36.94 on Friday. Genomic Health has a one year low of $26.37 and a one year high of $37.07.

In other news, insider James J. Vaughn sold 1,379 shares of the stock in a transaction on Thursday, November 2nd. The stock was sold at an average price of $32.51, for a total value of $44,831.29. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Laura Leber sold 21,000 shares of the stock in a transaction on Friday, December 15th. The shares were sold at an average price of $33.29, for a total value of $699,090.00. The disclosure for this sale can be found here. Over the last three months, insiders have sold 57,379 shares of company stock valued at $1,840,621. Corporate insiders own 46.20% of the company’s stock.

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Vanguard Group Inc. lifted its holdings in shares of Genomic Health by 6.8% in the second quarter. Vanguard Group Inc. now owns 1,670,622 shares of the medical research company’s stock valued at $54,379,000 after purchasing an additional 106,452 shares in the last quarter. Renaissance Technologies LLC lifted its holdings in shares of Genomic Health by 10.9% in the second quarter. Renaissance Technologies LLC now owns 813,300 shares of the medical research company’s stock valued at $26,473,000 after purchasing an additional 80,100 shares in the last quarter. State Street Corp lifted its holdings in shares of Genomic Health by 2.5% in the second quarter. State Street Corp now owns 517,313 shares of the medical research company’s stock valued at $16,840,000 after purchasing an additional 12,696 shares in the last quarter. Schwab Charles Investment Management Inc. lifted its holdings in shares of Genomic Health by 1.2% in the third quarter. Schwab Charles Investment Management Inc. now owns 503,244 shares of the medical research company’s stock valued at $16,150,000 after purchasing an additional 5,904 shares in the last quarter. Finally, Eagle Asset Management Inc. lifted its holdings in shares of Genomic Health by 18.4% in the second quarter. Eagle Asset Management Inc. now owns 379,473 shares of the medical research company’s stock valued at $12,351,000 after purchasing an additional 58,920 shares in the last quarter. Institutional investors own 89.61% of the company’s stock.

TRADEMARK VIOLATION WARNING: “Genomic Health (GHDX) Upgraded to “Hold” by ValuEngine” was originally reported by Watch List News and is the sole property of of Watch List News. If you are viewing this piece on another domain, it was copied illegally and republished in violation of US and international trademark & copyright laws. The correct version of this piece can be read at https://www.watchlistnews.com/genomic-health-ghdx-upgraded-to-hold-by-valuengine/1772372.html.

Genomic Health Company Profile

Genomic Health, Inc is a healthcare company that provides genomic-based diagnostic tests to personalize cancer treatment. The Company develops and commercializes genomic-based clinical laboratory services. The Company’s Oncotype IQ Genomic Intelligence Platform is consisted of its flagship line of Oncotype DX gene expression tests, as well as its Oncotype SEQ Liquid Select test.

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for Genomic Health (NASDAQ:GHDX)

Receive News & Ratings for Genomic Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genomic Health and related companies with MarketBeat.com's FREE daily email newsletter.